Browse > Article
http://dx.doi.org/10.5808/gi.22030

Two novel mutations in ALDH18A1 and SPG11 genes found by whole-exome sequencing in spastic paraplegia disease patients in Iran  

Komachali, Sajad Rafiee (Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences)
Siahpoosh, Zakieh (Department of Biology, Faculty of Science, University of Sistan and Baluchestan)
Salehi, Mansoor (Cellular, Molecular and Genetics Research Center, Isfahan University of Medical Sciences)
Abstract
Hereditary spastic paraplegia is a not common inherited neurological disorder with heterogeneous clinical expressions. ALDH18A1 (located on 10q24.1) gene-related spastic paraplegias (SPG9A and SPG9B) are rare metabolic disorders caused by dominant and recessive mutations that have been found recently. Autosomal recessive hereditary spastic paraplegia is a common and clinical type of familial spastic paraplegia linked to the SPG11 locus (locates on 15q21.1). There are different symptoms of spastic paraplegia, such as muscle atrophy, moderate mental retardation, short stature, balance problem, and lower limb weakness. Our first proband involves a 45 years old man and our second proband involves a 20 years old woman both are affected by spastic paraplegia disease. Genomic DNA was extracted from the peripheral blood of the patients, their parents, and their siblings using a filter-based methodology and quantified and used for molecular analysis and sequencing. Sequencing libraries were generated using Agilent SureSelect Human All ExonV7 kit, and the qualified libraries are fed into NovaSeq 6000 Illumina sequencers. Sanger sequencing was performed by an ABI prism 3730 sequencer. Here, for the first time, we report two cases, the first one which contains likely pathogenic NM_002860: c.475C>T: p.R159X mutation of the ALDH18A1 and the second one has likely pathogenic NM_001160227.2: c.5454dupA: p.Glu1819Argfs Ter11 mutation of the SPG11 gene and also was identified by the whole-exome sequencing and confirmed by Sanger sequencing. Our aim with this study was to confirm that these two novel variants are direct causes of spastic paraplegia.
Keywords
metabolism; mutation; neurological disorder; polyneuropathy; spastic paraplegia; whole-exome sequencing;
Citations & Related Records
연도 인용수 순위
  • Reference
1 de Koning TJ. Amino acid synthesis deficiencies. J Inherit Metab Dis 2017;40:609-620.   DOI
2 Koh K, Ishiura H, Beppu M, Shimazaki H, Ichinose Y, Mitsui J, et al. Novel mutations in the ALDH18A1 gene in complicated hereditary spastic paraplegia with cerebellar ataxia and cognitive impairment. J Hum Genet 2018;63:1009-1013.   DOI
3 Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, et al. The GeneCards Suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics 2016;54:1.30.1-1.30.33.
4 Magini P, Marco-Marin C, Escamilla-Honrubia JM, Martinelli D, Dionisi-Vici C, Faravelli F, et al. P5CS expression study in a new family with ALDH18A1-associated hereditary spastic paraplegia SPG9. Ann Clin Transl Neurol 2019;6:1533-1540.   DOI
5 Coutelier M, Goizet C, Durr A, Habarou F, Morais S, Dionne-Laporte A, et al. Alteration of ornithine metabolism leads to dominant and recessive hereditary spastic paraplegia. Brain 2015;138:2191-2205.   DOI
6 Stevanin G, Santorelli FM, Azzedine H, Coutinho P, Chomilier J, Denora PS, et al. Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet 2007;39:366-372.   DOI
7 Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Aguilera MA, Meyer R, et al. VarSome: the human genomic variant search engine. Bioinformatics 2019;35:1978-1980.   DOI
8 Boutry M, Pierga A, Matusiak R, Branchu J, Houllegatte M, Ibrahim Y, et al. Loss of spatacsin impairs cholesterol trafficking and calcium homeostasis. Commun Biol 2019;2:380.   DOI
9 Slavotinek AM, Pike M, Mills K, Hurst JA. Cataracts, motor system disorder, short stature, learning difficulties, and skeletal abnormalities: a new syndrome? Am J Med Genet 1996;62:42-47.   DOI
10 Lallemant-Dudek P, Darios F, Durr A. Recent advances in understanding hereditary spastic paraplegias and emerging therapies. Fac Rev 2021;10:27.
11 Ionita-Laza I, McCallum K, Xu B, Buxbaum JD. A spectral approach integrating functional genomic annotations for coding and noncoding variants. Nat Genet 2016;48:214-220.   DOI
12 Shihab HA, Rogers MF, Gough J, Mort M, Cooper DN, Day IN, et al. An integrative approach to predicting the functional effects of non-coding and coding sequence variation. Bioinformatics 2015;31:1536-1543.   DOI
13 Liu X, Li C, Mou C, Dong Y, Tu Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. Genome Med 2020;12:103.   DOI
14 Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods 2014;11:361-362.   DOI
15 Ewing B, Hillier L, Wendl MC, Green P. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Res 1998;8:175-185.   DOI
16 Fortelny N, Pavlidis P, Overall CM. The path of no return: truncated protein N-termini and current ignorance of their genesis. Proteomics 2015;15:2547-2552.   DOI
17 Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 2018;46:W296-W303.   DOI
18 Koh K, Takaki R, Ishiura H, Tsuji S, Takiyama Y. SPG9A with the new occurrence of an ALDH18A1 mutation in a CMT1A family with PMP22 duplication: case report. BMC Neurol 2021;21:64.   DOI
19 Steenhof M, Kibaek M, Larsen MJ, Christensen M, Lund AM, Brusgaard K, et al. Compound heterozygous mutations in two different domains of ALDH18A1 do not affect the amino acid levels in a patient with hereditary spastic paraplegia. Neurogenetics 2018;19:145-149.   DOI
20 Wei Q, Dong HL, Pan LY, Chen CX, Yan YT, Wang RM, et al. Clinical features and genetic spectrum in Chinese patients with recessive hereditary spastic paraplegia. Transl Neurodegener 2019;8:19.   DOI
21 Tian Y, Pesaran T, Chamberlin A, Fenwick RB, Li S, Gau CL, et al. REVEL and BayesDel outperform other in silico meta-predictors for clinical variant classification. Sci Rep 2019;9:12752.   DOI
22 Skidmore DL, Chitayat D, Morgan T, Hinek A, Fischer B, Dimopoulou A, et al. Further expansion of the phenotypic spectrum associated with mutations in ALDH18A1, encoding Delta(1)-pyrroline-5-carboxylate synthase (P5CS). Am J Med Genet A 2011;155A:1848-1856.
23 Seri M, Cusano R, Forabosco P, Cinti R, Caroli F, Picco P, et al. Genetic mapping to 10q23.3-q24.2, in a large Italian pedigree, of a new syndrome showing bilateral cataracts, gastroesophageal reflux, and spastic paraparesis with amyotrophy. Am J Hum Genet 1999;64:586-593.   DOI
24 Quang D, Chen Y, Xie X. DANN: a deep learning approach for annotating the pathogenicity of genetic variants. Bioinformatics 2015;31:761-763.   DOI
25 Ewing B, Green P. Base-calling of automated sequencer traces using phred. II. Error probabilities. Genome Res 1998;8:186-194.   DOI
26 Yang J, Yan R, Roy A, Xu D, Poisson J, Zhang Y. The I-TASSER Suite: protein structure and function prediction. Nat Methods 2015;12:7-8.
27 Bellofatto M, De Michele G, Iovino A, Filla A, Santorelli FM. Management of hereditary spastic paraplegia: a systematic review of the literature. Front Neurol 2019;10:3.   DOI
28 Hauser S, Poenisch M, Schelling Y, Hoflinger P, Schuster S, Teegler A, et al. mRNA as a novel treatment strategy for hereditary spastic paraplegia type 5. Mol Ther Methods Clin Dev 2019;15: 359-370.   DOI